$IFRX Up 25% Premarket! 🚀 🔹 InflaRx moving after announcing advancement of izicopan into ANCA-associated vasculitis and select renal diseases 📈 🔹 Company is

$IFRX Up 25% Premarket! 🚀 🔹 InflaRx moving after announcing advancement of izicopan into ANCA-associated vasculitis and select renal diseases 📈 🔹 Company is targeting AAV first, with plans to establish rapid proof-of-concept in additional life-threatening kidney diseases 🧬 🔹 Capital Markets Da…